<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963401</url>
  </required_header>
  <id_info>
    <org_study_id>B7931030</org_study_id>
    <secondary_id>2018-004241-16</secondary_id>
    <nct_id>NCT03963401</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis</brief_title>
  <official_title>A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PF-06700841 TO EVALUATE THE EFFICACY AT 16 WEEKS AND TO EVALUATE THE SAFETY AND EFFICACY UP TO 1 YEAR IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to
      evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">January 12, 2021</completion_date>
  <primary_completion_date type="Actual">April 6, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects achieving an ACR20 response</measure>
    <time_frame>Week 16</time_frame>
    <description>The proportion of subjects achieving an American College of Rheumatology 20 (ACR20) response at Week 16.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of TNF-naive subjects achieving an ACR20 response</measure>
    <time_frame>Week 16</time_frame>
    <description>The proportion of subjects achieving an ACR20 response at Week 16 in the subgroup of subjects who are TNF-alpha inhibitor na√Øve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving an ACR20 response</measure>
    <time_frame>Week 2, 4, 8, 12, 20, 28, 36, 44, and 52</time_frame>
    <description>The proportion of subjects achieving an ACR20 response at all treatment timepoints except Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving an ACR50 response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>The proportion of subjects achieving an ACR50 response at all treatment timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving an ACR70 response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>The proportion of subjects achieving an ACR70 response at all treatment timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the ACR response criteria components</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the ACR response criteria components (Tender/painful joint count, Swollen joint count, Patient's Assessment of Arthritis Pain, Patient's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, Health Assessment Questionnaire [HAQ] disability index [DI], and hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving a Psoriasis Area and Severity Index 75/90/100 (PASI75/90/100) response</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>The proportion of subjects achieving a Psoriasis Area and Severity Index 75/90/100 (PASI75/90/100) response at all treatment timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the enthesitis score using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index.</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the enthesitis score using the Spondyloarthritis Research Consortium of Canada [SPARCC] Enthesitis Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the enthesitis score using the Leeds Enthesitis Index.</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the enthesitis score using the Leeds Enthesitis Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Dactylitis Severity Score</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the Dactylitis Severity Score at all treatment timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Nail Psoriasis Severity Index (NAPSI) Score</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the Nail Psoriasis Severity Index (NAPSI) Score at all treatment timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Patient's Global Joint and Skin Assessment Visual Analog Scale (PGJS VAS)</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the Patient's Global Joint and Skin Assessment Visual Analog Scale (PGJS VAS) at all treatment timepoints. Scale will be 100 mm in length.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT Fatigue)</measure>
    <time_frame>Week 2, 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT Fatigue) at all treatment timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Short Form 36 Health Survey (SF 36) Version 2, Acute</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the Short Form 36 Health Survey (SF 36) Version 2, Acute, at all treatment timepoints except Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving Minimal Disease Activity (MDA) and Very Low Disease Activity (VLDA) response</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>The proportion of subjects achieving Minimal Disease Activity (MDA) and Very Low Disease Activity (VLDA) response at all treatment timepoints except Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA)</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the Disease Activity Index for Reactive Arthritis/PsA (DAREA/DAPSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving the Psoriatic Arthritis Response Criteria (PsARC)</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>The proportion of subjects achieving the Psoriatic Arthritis Response Criteria (PsARC) at all treatment timepoints except Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)</measure>
    <time_frame>Week 4, 8, 12, 16, 20, 28, 36, 44, and 52</time_frame>
    <description>Change from baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS) at all treatment timepoints except Week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline through Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued From the Study Due to Treatment-Emergent AEs</measure>
    <time_frame>Baseline through Week 56</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>PF-06700841 60 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 60 mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 30 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 30 mg once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 10 mg once daily followed by 60 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 10 mg once daily followed by 30 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily followed by 60 mg once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily followed by 30 mg once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841</intervention_name>
    <description>Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.</description>
    <arm_group_label>PF-06700841 10 mg once daily followed by 30 mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 10 mg once daily followed by 60 mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 30 mg once daily</arm_group_label>
    <arm_group_label>PF-06700841 60 mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.</description>
    <arm_group_label>Placebo once daily followed by 30 mg once daily</arm_group_label>
    <arm_group_label>Placebo once daily followed by 60 mg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active arthritis at screening/baseline as indicated by &gt;/= 3 tender/painful and 3
             swollen joints.

          -  Active plaque psoriasis at screening and baseline.

        Exclusion Criteria:

          -  Non-plaque forms of psoriasis (with exception of nail psoriasis).

          -  History of autoimmune rheumatic disease other than PsA; also prior history of or
             current, rheumatic inflammatory disease other than PsA.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Research Unit</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Trimontium OOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Pulmed&quot;</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment ''Plovdiv'' AD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4027</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;Pirogov&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Diagnostic-Consulting Center XVII - Sofia&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1505</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.K.N. Arthrocentrum s.r.o.</name>
      <address>
        <city>Hlucin</city>
        <zip>748 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Czech a.s.</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Prague s.r.o.</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL PLUS s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innomedica OU</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Basic Research</name>
      <address>
        <city>Tallinn</city>
        <zip>10128</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>11312</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualiclinic Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITAL MEDICAL CENTER Orvosi es Fogorvosi Kozpont</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences, Kauno klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Osteoporosis Center</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-09310</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZDROWIE Osteo-Medic s.c. L. I A. Racewicz, A. i J. Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk Nowak Sp. Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zespol Poradni Specjalistycznych &quot;REUMED&quot; Filia nr 2</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Lecznica Mak-Med s.c.</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia - Centrum Medyczne Nowa Sol</name>
      <address>
        <city>Nowa Sol</city>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ai Centrum Medyczne Sp. z o.o. Sp. k.</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska Prof. UM dr hab. med. Pawel Hrycaj</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCMed Oddzial Sochaczew</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NASZ LEKARZ Przychodnie Medyczne</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REUMATIKA - Centrum Reumatologii NZOZ</name>
      <address>
        <city>Warszawa</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;Family Outpatient clinic #4&quot;</name>
      <address>
        <city>Korolev</city>
        <state>Moscow Region</state>
        <zip>141060</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FGBOU VO &quot;Orenburg State Medical University&quot; of the Ministry of Health of the Russian Federation</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GBUZ &quot;Orenburg Regional Clinical Hospital&quot;</name>
      <address>
        <city>Orenburg</city>
        <zip>460018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of the Republic of Karelia &quot;Republican Hospital n. a. V.A. Baranov&quot;</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185910</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBEI of HE &quot;Ryazan State Medical University n. a academician I.P.Pavlov&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBI of Ryazan Region &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Ryazan</city>
        <zip>390039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company &quot;Sanavita&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GUZ &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC &quot;BioMed&quot;</name>
      <address>
        <city>Vladimir</city>
        <zip>600005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution of Yaroslavl Region</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Rheumatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Treatment and Rehabilitation Niska Banja</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodny ustav reumatickych chorob</name>
      <address>
        <city>Piestany</city>
        <zip>921 12</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Zuzana Cizmarikova, s.r.o.</name>
      <address>
        <city>Poprad</city>
        <zip>058 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REUMEX s.r.o.</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>979 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario A Coruna</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Quironsalud Infanta Luisa</name>
      <address>
        <city>Sevilla</city>
        <zip>41010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Belarus</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7931030</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <reference>
    <citation>Banfield C, Scaramozza M, Zhang W, Kieras E, Page KM, Fensome A, Vincent M, Dowty ME, Goteti K, Winkle PJ, Peeva E. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis. J Clin Pharmacol. 2018 Apr;58(4):434-447. doi: 10.1002/jcph.1046. Epub 2017 Dec 21.</citation>
    <PMID>29266308</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

